ClinicalTrials.gg
CompletedNCT07054255Updated Jul 8, 2025

Bioequivalence Study of Ranolazine Extended-release Tablets in Healthy Chinese Subjects

A Phase 1 interventional study of Test formulation (Ranolazine extended-release tablets) and Reference formulation (Ranolazine extended-release tablets) in Healthy, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 4 years 9 months after the study started (first participant enrolled Sep 2020, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The present study was conducted with the objective of comparing the bioequivalence and safety of a single dose of ranolazine extended-release tablets (Test product) manufactured by Haisco Pharmaceutical Group Co., Ltd. with those of the reference product (Ranexa®, Gilead Sciences, Inc.) in Chinese healthy subjects under fasting and fed conditions

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects aged 18 or older, both male and female, with an appropriate gender ratio;
  2. Female subjects weight ≥ 45.0 kg and male subjects weight ≥ 50.0 kg, and of 19 to 26 kg/m\^2(inclusive);
  3. Subjects who have no plans to conceive or donate sperm/eggs during the trial period until 3 months after the end of the trial and voluntarily adopt effective physical measures.
  4. Prior to the trial, a detailed understanding of the nature, significance, potential benefits, potential inconvenience, risks, and discomfort of the trial was obtained, and the subjects voluntarily participated in the clinical trial. The subject was able to communicate well with the researchers, comply with the requirements of the entire study, and signed a written form.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who are known to be allergic to the drug component Ranolazine (including ) or similar substances, or those with an allergic constitution (such as allergies to two or more drugs, food, or pollen) (consultation);
  2. Subjects with a history of chronic or severe diseases or existing systemic diseases that may affect the research results, including those related to the blood system, circulatory system, digestive system, urinary system, respiratory system, nervous system, immune system, endocrine system, mental disorders, metabolic disorders, or any other conditions that may affect the research results (consultation);
  3. Subjects who have undergone major surgery or suffered severe trauma within the first 3 months (90 days) of screening, or who have undergone surgery that may significantly affect the in vivo process or safety evaluation of the study drug (consultation);
  4. Received vaccination within one month (30 days) before screening(consultation);
  5. Used any prescription medication (such as antihypertensive drugs) within 1 month (30 days) before screening, or used any over-the-counter medication (vitamins, herbal medicines) within 2 weeks before screening (consultation);
  6. Subjects who have participated in and used any clinical trial drug or medical device within 3 months (90 days) before the first administration, or those who plan to participate in other clinical trials during this study (consultation);
  7. Subjects who regularly drink alcohol within one month (30 days) before screening (drinking alcohol ≥ 3 times a week, and drinking 50 ° Baijiu ≥ 100 mL each time on average), or cannot abstain from alcohol during the test, or the alcohol breath test result is>0.000mg/mL (consultation, examination);
  8. Subjects who have been addicted to smoking (more than 5 cigarettes per day or an equivalent amount of tobacco) for the past 3 months (90 days) prior to screening or who cannot stop using any tobacco products during the trial period (consultation);
  9. Subjects who have lost blood/donated more than 400 mL (excluding physiological blood loss in females) within 2 months (60 days) prior to screening, or who have received blood transfusions/used blood products, or who plan to donate blood within 1 month (30 days) after the end of the trial (consultation);
  10. On a daily within 2 weeks prior to screening,consuming excessive amounts of foods that affect metabolism, such as grapefruit or beverages containing grapefruit; Consuming excessive amounts of tea, coffee, chocolate, cola, or foods/beverages containing their main ingredients every day (averaging 8 or more cups per day, 200 mL per cup); Diets rich in xanthine, flavonoids, and other components (consultation);
  11. Within 48 hours before the first administration, consume grapefruit or beverages containing grapefruit; Consuming tea, coffee, chocolate, cola, or foods/beverages containing their main ingredients; Consuming a diet rich in xanthine, flavonoids, and other components; Or those who engage in vigorous exercise (consultation);
  12. Subjects with a history of drug abuse or positive results in urine drug abuse screening (consultation, examination);
  13. Any positive subject in screening period virus serum blood examination ( surface antigen, antibody, antigen antibody, Treponema pallidum antibody);
  14. During the screening period, if the physical examination, vital signs, or laboratory test results are judged by clinical doctors to be abnormal and , or if the is prolonged (female QT>440 ms or male QT>420 ms), or if fasting blood glucose exceeds the values (examination);
  15. Pregnant or lactating women, or those who test positive for pregnancy (consultation, examination);
  16. Subjects who are prone to diarrhea, nausea, vomiting, bloating, or other gastrointestinal discomfort after drinking milk or dairy products, or who are prone to dizziness, headache, constipation, and nausea on a regular basis (consultation);
  17. Subjects with a history of needle dizziness, blood dizziness, or intolerance to venipuncture blood collection (for consultation and examination);
  18. Subjects with difficulty swallowing tablets/capsules (consultation);
  19. Subjects with special dietary requirements (such as vegetarians) or those who cannot adhere to a uniform diet during the trial period (consultation);
  20. Subjects who may not be able to cooperate with the completion of the study for other reasons, or the investigator may determine that they are not suitable for inclusion;
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Test formulation

    Ranolazine sustained-release tablets, specification: 500 mg, Haisco Pharmaceutical Co., Ltd.

    Drug: Test formulation (Ranolazine extended-release tablets)

  • Experimental
    Reference formulation

    Ranolazine sustained-release tablets (Ranexa®), specification: 500 mg, Gilead Sciences, Inc.

    Drug: Reference formulation (Ranolazine extended-release tablets)

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    The pharmacokinetic parameters of Ranolazine in plasma

    Time frame: From the start of administration to 48 hours post-dose

  2. AUC(0-t)

    The pharmacokinetic parameters of Ranolazine in plasma

    Time frame: From the start of administration to 48 hours post-dose

  3. AUC(0-∞)

    The pharmacokinetic parameters of Ranolazine in plasma

    Time frame: From the start of administration to 48 hours post-dose

Secondary outcomes

  1. AEs

    The incidence and severity of AEs

    Time frame: From the time of signing ICF to the end of follow-up,up to 10 days

07

Study locations

1 site
  • Zhongda Hospital, Southeast University
    Nanjing, Jiangsu, China
08

References and documents

Publications

  • Chen X, Li Y, Ma G. Bioequivalence and Safety Study of Ranolazine Extended-Release Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: A Randomized, Open-Label, Single-Dose, Cross-Over, Comparative Pharmacokinetic Study. Clin Ther. 2026 Jan;48(1):88-94. doi: 10.1016/j.clinthera.2025.11.002. Epub 2025 Nov 25. PubMed 41298182 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Nov 2020, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 8, 2025
StartActual
Sep 6, 2020
Primary completionActual
Nov 9, 2020
CompletionActual
Dec 21, 2020
Last update
Jul 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07054255
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Sep 6, 2020
Primary completion
Nov 9, 2020
Completion
Dec 21, 2020
Last update
Jul 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion